Neuraxpharm
Neuraxpharm, a leading pharmaceutical company headquartered in Spain, is renowned for its commitment to improving the lives of patients with central nervous system (CNS) disorders. Founded in 1985, the company has established a strong presence across Europe, focusing on the development and distribution of innovative treatments for mental health conditions, including depression and anxiety. With a diverse portfolio of products, Neuraxpharm stands out for its specialised formulations and patient-centric approach. The company has achieved significant milestones, including strategic acquisitions that have expanded its market reach and enhanced its product offerings. As a trusted name in the pharmaceutical industry, Neuraxpharm continues to prioritise research and development, solidifying its position as a key player in the CNS market.
DitchCarbon Score
How does Neuraxpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neuraxpharm's score of 28 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neuraxpharm's reported carbon emissions
In 2025, Neuraxpharm reported total carbon emissions of approximately 917,000 kg CO2e, comprising 66,000 kg CO2e from Scope 2 and 851,000 kg CO2e from Scope 3 emissions. The previous year, 2024, saw emissions of about 578,000 kg CO2e, with 8,000 kg CO2e from Scope 2 and 570,000 kg CO2e from Scope 3. In 2023, the company recorded around 454,000 kg CO2e, including 1,000 kg CO2e from Scope 2 and 453,000 kg CO2e from Scope 3. Neuraxpharm's emissions data from 2022 indicates a significant contribution from Scope 1 and 2, totalling approximately 3,000,000 kg CO2e, with 1,776,150 kg CO2e from Scope 1 and 1,461,700 kg CO2e from Scope 2. The 2021 figures were about 1,138,000 kg CO2e, with 389,000 kg CO2e from Scope 1 and 749,000 kg CO2e from Scope 2. In 2020, emissions were approximately 771,000 kg CO2e, consisting of 446,000 kg CO2e from Scope 2 and 325,000 kg CO2e from Scope 3. Currently, Neuraxpharm has not set any specific reduction targets or initiatives, nor do they participate in the Science Based Targets initiative (SBTi). The company does not inherit emissions data from any parent organisation, indicating that all reported figures are self-generated.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 0,000,000 | - | - | - |
| Scope 2 | 446,000 | 000,000 | 0,000,000 | 0,000 | 0,000 | 00,000 |
| Scope 3 | 325,000 | - | - | 000,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neuraxpharm is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
